Skip to main content

Home/ Health and Fitness Club/ Group items tagged medical-research-innovation

Rss Feed Group items tagged

pharmacybiz

How to Learn About the Latest Medical Research Trends: 6 Essential Tips - 0 views

  •  
    In the fast-evolving world of medicine, staying updated with the latest research trends is crucial for healthcare professionals and researchers alike. This helps ensure that patient care is based on the best available evidence and keeps professionals at the forefront of innovations and advancements. Here are six essential tips on how to stay informed about the latest medical research trends. 1. Utilize Trusted Sources The vast amount of information available online can be overwhelming, making it essential to discern credible sources from unreliable ones. Here are some strategies to help: Identify Reputable Journals and Databases: Publications like The New England Journal of Medicine, The Lancet, and JAMA are renowned for their rigorous peer-review processes. Databases like PubMed and Google Scholar are also excellent for accessing a wide range of scientific papers. Check for Peer-Reviewed Articles: Peer review ensures that research has been evaluated by experts in the field, enhancing its credibility. Look for Author Credentials: Research conducted by established experts in the field is more likely to be trustworthy. Evaluate Institutional Affiliations: Research from reputable institutions and organizations often signifies high-quality work.
pharmacybiz

£260m to boost healthcare research and manufacturing : Govt - 0 views

  •  
    The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
John Gray

Medical Research Jobs - 0 views

  •  
    Imagine how far Medicine has taken the world. Just a few decades ago you hardly had medicines to cure the simplest of medical problems. Would you even believe that it wasn't until the late 1960s that Ibuprofen was invented? But now almost every issue you have can be solved with a pill, capsule or a simple visit to a specialist. This is all thanks to medical innovations brought about by intense research.
pharmacybiz

£100M Investment to Launch 20 Research Hubs Across the UK | Pharmacy News - 0 views

  •  
    The government has announced a £100 million public-private investment to establish 20 new commercial research delivery centres (CRDCs) across the UK, aimed at increasing access to innovative treatments and clinical trials in underserved communities. These centres will be set up in all four nations: England, Scotland, Wales, and Northern Ireland, acting as regional hubs for pioneering clinical trials. These trials will span various conditions, including cancer, obesity, and infectious diseases like flu and respiratory syncytial virus (RSV). The hubs will facilitate the swift launch of commercial studies, ensuring that patients can access experimental treatments as soon as possible. Health Minister Baroness Gillian Merron hailed the investment as "a powerful vote of confidence in the UK's leading research and life sciences sector." She noted that the new hubs will shift research into smaller communities, allowing more people to access cutting-edge treatments faster.
pharmacybiz

World's first ovarian cancer vaccine: University of Oxford awarded £600,000 f... - 0 views

  •  
    Researchers at the University of Oxford have received a grant of up to £600,000 from Cancer Research UK to develop the world's first vaccine to prevent ovarian cancer. Named OvarianVax, the innovative vaccine aims to train the immune system to recognise and attack the earliest stages of ovarian cancer. Ovarian cancer is the sixth most common cancer among women in the UK, with approximately 7,500 new cases diagnosed annually-equating to about 21 cases each day. It is also a leading cause of cancer-related deaths in women, with around 4,100 deaths each year, accounting for five per cent of all cancer deaths in UK females. Projections suggest that by 2038-2040, there could be around 9,400 new cases of ovarian cancer annually in the UK. Several factors influence a person's risk of developing ovarian cancer, including age, genetics, hormone replacement therapy (HRT), smoking, asbestos exposure, medical conditions such as endometriosis or diabetes, and obesity. Faults in the inherited genes, particularly BRCA1 and BRCA2, are linked to a higher risk of ovarian cancer, contributing to 5-15 per cent of cases.
pharmacybiz

Chiesi Farmaceutici acquires Amryt Pharma - 0 views

  •  
    Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.
pharmacybiz

Public Willing to Pay More for Medicines for Severe Conditions, New Report Reveals | AB... - 0 views

  •  
    A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.
Clint Winters

The Conolidine Inventor: Revolutionize Pain Relief Naturally - 4 views

  •  
    The research of Conolidine as a pain reliever is a milestone in pain management, attributed to pioneering efforts in pharmacology and natural compound research. Known for its unique pain-relieving properties without addictive risks, Conolidine's potential lies in its natural origins and the innovative mind that recognized its value. The inventor of Conolidine has done thorough research on the bark of the crepe jasmine plant and also paid attention to Taebermontana Divaricata and its usage in traditional medicines. His contributions from isolation to the refining of the Conolidine compound are commendable to ensure this compound for safe, modern therapeutic use. The invention of Conolidine represents a new era in pain management, especially amid rising concerns over opioid addiction and dependency issues. The inventor's work has brought forward a solution that addresses chronic pain while bypassing the common side effects of traditional pain medications. Thanks to this innovative contribution, Conolidine has paved the way for future research into other plant-based compounds, inspiring hope for more natural and accessible health solutions. The Conolidine inventor has not only introduced a potentially life-changing product but has also set a precedent for the future of natural medicine and pain relief.
1 - 8 of 8
Showing 20 items per page